A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention

John T. Harris, John D. Roache, Joseph E. Thornton

Resultado de la investigación: Review articlerevisión exhaustiva

13 Citas (Scopus)

Resumen

In the human central nervous system, the gamma-aminobutyric acid (GABA) type A receptor complex undergoes changes with both acute and chronic exposure to sedative-hypnotic drugs. These changes contribute to both the acute effects of these drugs as well as the chronic effects of sedative-hypnotic dependence, withdrawal, and drug craving. Clinically these chronic effects are difficult to treat in patients dependent on ethanol or benzodiazepines. Valproate may return the GABA type A receptor function to a state more closely resembling its normal function. By this mechanism, it is possible to reduce the symptoms of sedative-hypnotic withdrawal and relapse.

Idioma originalEnglish (US)
Páginas (desde-hasta)319-323
Número de páginas5
PublicaciónAlcohol and Alcoholism
Volumen35
N.º4
DOI
EstadoPublished - 2000

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Toxicology
  • Psychiatry and Mental health

Huella

Profundice en los temas de investigación de 'A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention'. En conjunto forman una huella única.

Citar esto